Zhang Dongdong

Prof. Zhang Dongdong

Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, China
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YJYanxia Jin
Yanxia Jin
QYQian Yang
Qian Yang
LLLi Liang
Li Liang
LDLu Ding
Lu Ding
YLYuxing Liang
Yuxing Liang
FZFuling Zhou
Fuling Zhou
The increase in the levels of reactive oxygen species (ROS) in acute myeloid leukemia (AML) patients has been previously described; thus, it is important to regulate ROS levels in AML. Flow cytometry were used to assess the in vitro effect of compound kushen injection (CKI). Quantitative proteomics were used to analyse the mechanism. The AML patient-derived xenograft (PDX) model were used to evaluate the in vivo effect of CKI. We found that intracellular ROS levels in AML cells were decreased, the antioxidant capacity were increased when treated with CKI. CKI inhibited the proliferation of AML cells and enhanced the cytotoxicity of AML cells, which has few toxic effects on haematopoietic stem cells (HSCs) and T cells. At the single-cell level, individual AML cells died gradually by CKI treatment on optofluidic chips. CKI promoted apoptosis and arrested cell cycle at G1/G0 phase in U937 cells. Furthermore, higher peroxiredoxin-3 (Prdx3) expression levels were identified in CKI-treated U937 cells through quantitative proteomics detection. Mechanically, the expression of Prdx3 and peroxiredoxin-2 (Prdx2) was up-regulated in CKI-treated AML cells, while thioredoxin 1 (Trx1) was reduced. Laser confocal microscopy showed that the proteins Prdx2 could be Interacted with Trx1 by CKI treatment. In vivo, the survival was longer and the disease was partially alleviated by decreased CD45+ immunophenotyping in peripheral blood in the CKI-treated group in the AML PDX model. Antioxidant CKI possess better clinical application against AML through the Prdxs/ROS/Trx1 signalling pathway.

23 December 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZDZhang Dongdong
Zhang Dongdong
ZLZiyi Luo
Ziyi Luo
YJYanxia Jin
Yanxia Jin
YCYanling Chen
Yanling Chen
TYTian Yang
Tian Yang
FZFuling Zhou
Fuling Zhou
Acute myeloid leukemia (AML) is a hematological malignancy with a poor prognosis attributed to elevated reactive oxygen species (ROS) levels. Thus, agents that inhibit ROS generation in AML should be exploited. Azelaic acid (AZA), a small molecular compound, can scavenge ROS and other free radicals, exerting antitumor effects on various tumor cells. Herein, this study evaluated the antileukemic activity of AZA against AML via regulation of the ROS signaling pathway. We found that AZA reduced intracellular ROS levels and increased total antioxidant capacity in AML cell lines and AML patient cells. AZA suppressed the proliferation of AML cell lines and AML patient cells, expending minimal cytotoxicity on healthy cells. Laser confocal microscopy showed that AZA-treated AML cells surged and ruptured gradually on microfluidic chips. Additionally, AZA promoted AML cell apoptosis and arrested the cell cycle at the G1 phase. Further analysis demonstrated that peroxiredoxin (Prdx) 2 and Prdx3 were upregulated in AZA-treated AML cells. In vivo, AZA prolonged survival and attenuated AML by decreasing CD33+ immunophenotyping in the bone marrow of a patient-derived xenograft AML model. Furthermore, mice in the AZA-treated group had an increased antioxidant capacity and Prdx2/Prdx3 upregulation. The findings indicate that AZA may be a potential agent against AML by regulating the Prdxs/ROS signaling pathway.

1 July 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
ZDZhang Dongdong
Zhang Dongdong
YZYufan Zhu
Yufan Zhu
YJYanxia Jin
Yanxia Jin
NKNatasha Mupeta Kaweme
Natasha Mupeta Kaweme
YDYouhong Dong
Youhong Dong
Hyperleukocytosis is a hematologic crisis caused by excessive proliferation of leukemic cells and has a relatively high early mortality due to a series of severe complications. Therefore, prompt and effective intervention is required. Leukapheresis performed using apheresis equipment to separate leukocytes from peripheral blood, at the same time returns autologous plasma, platelets and erythrocytes to the patient, is applied clinically for the treatment of hyperleukocytosis. Leukapheresis not only removes excessive leukocytes rapidly and corrects metabolic abnormalities but also alleviates the symptoms of leukostasis. In addition, the procedure of leukapheresis is generally well tolerated. Leukapheresis has become one of the most imperative adjuvant therapies to treat hyperleukocytosis, especially in the patient who was not inappropriate to cytoreduce with Ara-C or hydroxyurea. In this review, we present the background of leukapheresis development and highlight its clinical application in hyperleukocytic leukemia patients.

11 June 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GHGuoxin Huang
Guoxin Huang
YWYaojie Wang
Yaojie Wang
BQBingqing Qin
Bingqing Qin
JZJing Zeng
Jing Zeng
HTHuazhang Tan
Huazhang Tan
QWQiuyang Wang
Qiuyang Wang
Purpose: To use data from the Global Burden of Disease (GBD) Study 2019 to report the global, regional and national rates and trends of deaths incidence, prevalence, disability-adjusted life years (DALYs) for Nasopharynx cancer (NPC) in adolescents and young adults (AYAs). Methods: Data from the GBD 2019 were used to analyze deaths incidence, prevalence and DALYs due to NPC at global, regional, and national levels. Joinpoint regression analysis was used to calculate the average annual percentage changes (AAPC). The association between incidence, prevalence and DALYs and socioeconomic development was analyzed using the GBD Socio-demographic Index (SDI). Finally, projections were made until 2030 and calculated in Nordpred. Results: The incidence, prevalence, death and DALYs rates (95%UI) due to NPC 0.96 (0.85–1.09, 6.31 (5.54–7.20),0.20 (0.19–0.22), and 12.23(11.27–13.29) in 2019, respectively. From 1990 to 2019, the incidence and prevalence rates increased by 1.79 (95% CI 1.03 to 2.55) and 2.97(95% CI 2.13 to 3.82) respectively while the deaths and DALYs rates declined by 1.64(95%CI 1.78 to 1.49) and 1.6(95%CI 1.75 to 1.4) respectively. Deaths and DALYs rates in South Asia, East Asia, North Africa and Middle East decreased with SDI. Incidence and prevalence rates in East Asia increased with SDI. At the national level, the incidence and prevalence rates are high in China, Taiwan(China), Singapore, Malaysia, Brunel Darussalam, Algeria, Tunisia, Libya and Malta. Meanwhile, the deaths and DALYs rates are still high in Malaysia, Brunel Darussalam, Greenland and Taiwan(Province of China). The deaths and DALYs rates are low in Honduras, Finland and Norway. From the 2020 to 2030, ASIR、ASPR and ASDR in most regions are predicted to stable, but DALYs tends to decline. Conclusion: NPC in AYAs is a significant global public problem. The incidence, prevalence, and DALYs rates vary widely by region and country. Therefore different regions and countries should be targeted to improve the disease burden of NPC.

1 November 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SLShuwen Lei
Shuwen Lei
ZDZhang Dongdong
Zhang Dongdong
YQYunyue Qi
Yunyue Qi
SCSharmin Reza Chowdhury
Sharmin Reza Chowdhury
RSRan Sun
Ran Sun
FJFaqin Jiang
Faqin Jiang

23 February 2026 in Chemical & Biomedical Imaging
Verified
Journal Article
Open access
QWQing Wang
Qing Wang
ZGZhibin Guo
Zhibin Guo
ZCZiqun Chen
Ziqun Chen
CWCaiyu Wang
Caiyu Wang
YYYahui Yang
Yahui Yang
YLYujiao Liu
Yujiao Liu
The acidic tumor microenvironment (TME) presents a key pathological hallmark that can be exploited for targeted therapeutic and diagnostic interventions. This review systematically outlines the design and application of pH-responsive materials in biomedical imaging and therapy, emphasizing their role in achieving spatial and temporal control over drug delivery and imaging contrast. We first detail the fundamental chemical mechanisms underpinning pH responsiveness, including dynamic covalent bonds (e.g., acylhydrazone, imine, orthoester, and borate ester), metal–ligand coordination bonds, and pH-dependent noncovalent interactions. These principles are then translated into a variety of nanocarrier platforms, such as polymeric micelles, liposomes, hydrogels, metal–organic frameworks (MOFs), PROTAC conjugates, and self-assembling peptides, all of which are designed to undergo structural or functional changes in response to acidic conditions. The convergence of these smart materials with advanced imaging modalities has enabled transformative applications, including activatable probes for high-contrast functional imaging, multistimuli responsive theranostics, organelle-precision targeting, and spatiotemporally programmed release systems. These innovations collectively enhance diagnostic accuracy, therapeutic specificity, and the potential for real-time treatment monitoring. However, clinical translation remains challenged by issues related to reproducible synthesis, long-term biocompatibility, and the complex heterogeneity of in vivo environments. Future advancements are anticipated to focus on the integration of artificial intelligence for material design, the development of closed-loop feedback systems, and rigorous translational studies to bridge the gap between laboratory innovation and clinical application.